Therapeutic targeting of non-cellular structures

1. A composition comprising a chimeric protein consisting of:

(a) one or more modified signaling agents, wherein at least one signaling agent is a human interferon alpha 2 (IFNα2) comprising an amino acid sequence having at least 98% identity with a sequence selected from SEQ ID NO: 1 or 2 and having one or more mutations at one or more amino acid positions 144-154;

(b) one or more targeting moieties, wherein at least one targeting moiety comprises a single-domain antibody recognition domain which specifically binds to non-cellular tenascin-CA1 and,

wherein the one or more mutations confer reduced affinity or activity to IFNα2 that is restorable by attachment to the one or more targeting moieties,

wherein at least one targeting moiety and signaling agent are connected with one or more flexible linkers.

2. The chimeric protein of claim 1 , wherein the single-domain antibody is a recombinant heavy-chain-only antibody (VHH) or a single-chain antibody (scFv).

3. The chimeric protein of claim 2 , wherein the recognition domain is a V HH or a humanized V HH .

4. The chimeric protein of claim 1 , wherein the modified human IFNα2 comprises one or more mutations at a position selected from M148, R149, and L153.

5. The chimeric protein of claim 4 , wherein the modified human IFNα2 comprises one or more mutations selected from M148A, R149A, and L153A.

6. The chimeric protein of claim 1 , wherein the chimeric protein comprises two or more signaling agents or two or more targeting moieties or two or more of both.

7. The chimeric protein of claim 6 , wherein one of the targeting moieties is directed against Clec9A, CD8, CD20, PD-1, PD-L1, or CD3.

8. A pharmaceutical composition, comprising the chimeric protein of claim 1 .

9. A recombinant nucleic acid composition encoding the chimeric protein of claim 1 , or a component thereof.

10. A host cell comprising the nucleic acid of claim 9 .

11. A method for treating cancer, comprising administering an effective amount of the chimeric protein of claim 1 to a patient in need thereof.

12. The method of claim 11 , wherein the method prevents or reduces deregulation and/or disorganization of the non-cellular structure relative to a cancerous state.

13. The method of claim 11 , wherein the cancer is selected form one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; gastrointestinal cancer; glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer; small-cell lung cancer; non-small cell lung cancer; adenocarcinoma of the lung; squamous carcinoma of the lung; melanoma; myeloma; neuroblastoma; oral cavity cancer; ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma; B-cell lymphoma; low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; and chronic myeloblastic leukemia.